Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CDH17 CAR-T in CDH17-positive Advanced Solid Tumors
NCT06501183Phase 1Recruiting
- Sponsor
- Shanghai Pudong Hospital
- Start
- Jul 2024
- Primary completion
- May 2025
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CHM-2101 in solid tumor, sponsored by Shanghai Pudong Hospital. Primary endpoints: Adverse Events at 2 years, Serious Adverse Events at 2 years and 2 more. Started Jul 2024; status: recruiting.
02
Drugs
CHM-2101
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06501183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06501183.